This article was originally published in Start Up
Executive SummarySangart Inc. says it is the first company to thoroughly understand the mechanisms of cell-free hemoglobin in the body and has designed Hemospan to mimic the size and behavior of natural hemoglobin. Sangart believes that its science and simplified production method put it on track to create a safe, cost-effective, commercially viable hemoglobin-based oxygen carrier.
You may also be interested in...
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)